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The O2 allele: questioning the 
phenotypic definition of an  
ABO allele
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There are three main alleles in the ABO blood group system, A, 
B, and O.  The former two alleles encode glycosyltransferases 
resulting in the wild-type A and B phenotypes, whereas the 
latter allele does not encode a functional enzyme owing to a 
frameshift polymorphism in the majority of cases.  Thus the 
group O phenotype is the absence of A or B sugars.  More than 
15 years ago the O2 allele was described; this allele did not 
feature the usual crippling 261delG polymorphism, which up 
to that point was the hallmark of an allele encoding group O, 
but instead had several other nucleotide polymorphisms that 
reduced or eliminated the activity of its resulting protein.  The 
classification of this type of allele as encoding group O has 
been called into question of late as some individuals with an 
O2 allele appear to have a weak A phenotype.  Others with 
the same allele do not demonstrate any A antigens on their 
RBCs but might be involved in reverse typing discrepancies. 
Even within the same pedigree these alleles do not necessarily 
produce a consistent phenotype.  This paper will summarize 
the detailed biochemical and population-based evidence both 
for and against the O2 allele’s ability to create A antigens 
or the absence of anti-A in plasma.  Immunohematology 
2008;24:138–147.
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Introduction to the Concept of ABO Alleles
For a short period, things were simple in the 
nascent field of ABO molecular genetics.  There were 
three known alleles of the ABO gene, A1, B, and O, 
and they correlated well with the four major ABO 
phenotypes.  It was known that all three alleles con-
tained 1065 bases unequally divided among seven 
exons, and that A alleles consistently differed from 
B alleles at seven in-frame nucleotide residues (Fig. 
1), of which four of these single-nucleotide polymor-
phisms (SNPs) caused amino acid substitutions in the 
enzyme (Fig. 2).1–3  At that time it was also known that 
the O allele was one base shorter than the consensus 
A1 allele; the deletion of a G nucleotide at residue 261 
(261delG) introduced a frameshift mutation and a 
premature stop codon such that the protein was pre-
dicted to have only 117 of the usual 354 amino acids 
and completely lack an enzymatic center.1  Lacking 
the glycosyltransferase A (GTA) ability to transfer the 
A-determining sugar N-acetylgalactosamine (GalNAc) 
or the glycosyltransferase B (GTB) activity of trans-
ferring the B-determining moiety galactose (Gal), an 
O phenotype clearly is essentially the absence of A 
or B antigens.
Thus in the early part of the 1990s, three ABO al-
leles produced four phenotypes.  Those halcyon days 
were, however, the calm before the storm; shortly 
after the landmark description of the structure of the 
ABO gene by Yamamoto et al.,1 the alleles underlying 
various A and B subtype phenotypes were reported. 
Fig. 1. Summary of exonic SNPs in the alleles described in this paper. 
The A1 [A101] allele is the consensus allele to which all others 
are compared.  Vertical bars through the schematic allele 
indicate a consensus nucleotide.  UTR = untranslated region.
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It became clear that different SNPs could be manifest 
in a similar phenotype.  This is not surprising given 
that A and B subtypes are normally first detected in 
the blood bank by using serologic techniques that, 
in a relatively crude manner, determine the amount 
and type of A and B antigen expressed on the RBCs. 
A specific subtype SNP is seldom betrayed by its 
phenotype; however, the same SNP can sometimes 
give rise to different phenotypes.  Thus, almost 20 
years after the cloning of the ABO gene, there are 
many known SNPs underlying A and B subtype 
phenotypes, and the process of ABO genotyping is 
further complicated when hybrid alleles are added to 
the mix. In summary, the genetics of the ABO blood 
group is no longer simple.
But what about group O, the null phenotype of 
the ABO system?  Simply put, any allele that does not 
give rise to an A or B phenotype, no matter how weak, 
is de facto an O allele.  Given the heterogeneity and 
number of SNPs underlying A and B subtypes, why 
should we not assume that O alleles have an even 
greater variety of SNPs eliminating enzyme activity? 
How fine a line is there between an enzyme with 
greatly reduced activity and one completely devoid 
of activity?  And an even more intriguing question is 
whether the same enzyme can behave differently in 
different circumstances.
As initially described, the O allele was virtually 
identical to the consensus A1 allele (now also referred 
to as A101) save for the 261delG SNP.1  In time, other 
O alleles with the same 261delG SNP were described. 
The second most commonly encountered O allele, 
O1v [O02], has 10 SNPs scattered throughout exons 3 
through 7 including 261delG,4 as well as numerous 
SNPs in its introns that discriminate it from A101.5,6 
Despite sharing the 261delG SNP, O1 and O1v are not 
at all related in evolutionary terms.7,8  A variety of 
rare and common O alleles with and without 261delG 
(reviewed in Hosseini-Maaf et al.9 and Chester and 
Olsson10) have been deposited in the Blood Group 
Antigen Gene Mutation Database (dbRBC),11 which 
currently harbors 42 entries of alleles containing 
261delG.  O alleles that feature 261delG are broadly 
referred to as “deletional” O alleles owing to the 
nature of their crippling SNP, and they account for 
virtually all of the O alleles in all populations studied 
in which an O2 allele was not identified.  Lacking 
an active center, these deletional O alleles cannot 
give rise to functional enzymes, although it has been 
speculated that these truncated proteins might play 
a role as minor histocompatibility antigens.12  Thus, 
when a deletional O allele is inherited with a con-
sensus or subtype A or B allele, the RBC phenotype 
will be defined only by the allele in trans to the 
deletional O allele.
1. Do O Alleles with 802G>A Give Rise to 
GTA Activity? No.
As mentioned above, given the panoply of SNPs 
producing A and B subtypes, it should be somewhat 
surprising to find only one main genetic mechanism 
of eliminating A and B glycosyltransferase activity, 
namely 261delG.  But group O alleles are not devoid 
of their own intrigue.  Consider an interesting patient 
first described in 1993 by Yamamoto et al.13  Their 
patient likely had a B3 phenotype by modern subtype 
nomenclature (60% of this patient’s RBCs were 
agglutinated with anti-B reagents; this represents 
mixed field agglutination); thus their genotype was 
Fig. 2. Three-dimensional ribbon diagram of the ABO glycosyltrans-
ferase enzyme.  The numbered amino acid residues indicate 
those which differentiate GTA from GTB while highlighting 
residue 268, which is critical in causing the dramatic change 
in enzymatic activity in the O2 allele–encoded protein.  Figure 
generously supplied by Drs. Stephen Evans and Monica 
Palcic.
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expected to be B3/O as the authors assumed that 
a B3/B3 genotype was very rare.13  However, on 
sequencing exons 6 and 7, the 261delG SNP was 
not found and in fact no SNPs were discovered that 
would have limited the translation of this new allele’s 
transcript.  Thus, for the first time, an allele without 
apparent enzymatic activity that lacked the 261delG 
SNP had been discovered!  Other perturbations from 
the A101 allele were present: 297A>G, 526C>G, and 
802G>A.13  Remarkably, the former two SNPs are 
present in a wild-type B allele, whereas the 802G>A 
SNP was novel (Fig. 1).  802G>A predicts a Gly268Arg 
substitution in the enzyme; amino acid residue 268 is 
one of the four residues that discriminate a wild-type 
GTA from GTB and, along with the amino acid at 
residue 266, it helps to confer the enzyme’s donor 
sugar specificity.  The 526C>G SNP predicts an 
Arg176Gly amino acid mutation, which again is one 
of the four GTA versus GTB discriminating amino 
acids, although the amino acid at residue 176 is 
more likely involved in enzyme turnover rate, not in 
conferring donor sugar specificity (reviewed in Yazer 
and Palcic14).  The authors transfected HeLa cells with 
the cDNA of their newly discovered “nondeletional” 
O allele and could only detect background levels of A 
and B antigen expression by flow cytometry.13
One year later, Danish investigators Grunnet et 
al.15 gave this new O allele a name.  By PCR-RFLP 
analysis of 150 phenotypically group O blood donors 
and laboratory volunteers, they found 11 individuals 
who they described as having either an “A or a B allele 
without the (261delG) deletion.”15  Further analysis of 
this allele confirmed the finding by Yamamoto et al.13 
of a B allele–related 526G, and also found an A allele–
related 703G (Fig. 1).  This latter residue is another 
A versus B determining nucleotide.  By sequencing 
exons 6 and 7, these authors also confirmed the 
presence of both the 297A>G and 802G>A SNPs that 
had already been described.  It was now clear that 
this new allele was composed of both A and B allele 
sequences.  The Danish investigators thus recognized 
that the nondeletional allele they were describing 
was identical to the one published a year earlier, and 
they named it O2.15  As all 11 of their donors with the 
O2 allele were also heterozygous for the deletional O1 
allele, the authors calculated an O2 gene frequency 
of 3.7 percent in their population.  This frequency 
is within the range of O2 allele frequencies later 
reported in several populations.10  Grunnet et al. did 
not perform functional assays on the O2 enzyme, nor 
did they employ adsorption–elution to detect whether 
very small quantities of A antigen were present on 
RBCs from their O2 donor.15
The O2 allele surfaced again a few years later in 
studies on Ael16 and Ax subgroups.17  Even though it 
was striking to find this infrequent O allele present 
in several of the rare pedigrees presented,16,17 there 
were no data to suggest that O2 was able to increase 
the amount of A antigen expression when present, a 
finding that was consistent with the literature at that 
time.
In 2000 another comprehensive study focused on 
both healthy blood donors and patients with gastric 
carcinoma.18  The O2 gene frequency was established 
to be 4.2 percent and 3.9 percent, respectively, but 
this study was important for several other reasons. 
It was the first to sequence all seven exons of the O2 
gene, and in so doing it revealed two SNPs in exons 
2 and 5 that had not previously been detected in 
this allele.  The 53G>T SNP is interesting because it 
represented a polymorphism specific to the O2 allele; 
up to this point, the O2 gene appeared to be a hybrid 
of A and B alleles without any novel sequences of its 
own except for 802G>A, but the new data suggested 
that this allele had undergone its own evolution (Fig. 
1).18  Later investigators would reveal more similari-
ties between the O2 and A1 alleles in the upstream 
CCAAT-binding factor (CBF) enhancer region (both 
have only one 43-bp element as opposed to the other 
major alleles, which have four).19  Analysis of the 
introns of the O2 allele revealed that it shares some 
common sequences with other O alleles in introns 
2, 4, and 5, and with B alleles in intron 6, while 
also demonstrating a few unique SNPs in introns 2 
through 5.5,6
The authors of the previous studies on O2 pre-
dicted that if a protein was to be translated from this 
gene, it should contain all 354 amino acids and it 
should thus cross-react with antibodies to both the 
wild-type GTA and GTB enzymes themselves.  Indeed 
this latter postulate was shown to be the case; when 
Sf9 insect cells were transfected with the full-length 
O2 transcript, staining with an antibody that binds to 
amino acid sequences common to wild-type GTA and 
GTB revealed a Golgi pattern of localization for the 
O2 protein.  This pattern of staining was observed in 
most normal and neoplastic tissues from O1O2 gastric 
cancer patients.18  So whereas the O2 protein was 
expressed in its expected location, its functionality 
remained dubious.  Expression constructs of both 
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the full-length and soluble forms of the enzyme 
failed to show activity above background levels with 
either GalNAc or Gal.18  Similar findings had been 
demonstrated in 1996 when Yamamoto and McNeill20 
produced expression constructs of an A101 gene and 
mutated the amino acid at residue 268 with all 20 
amino acids; when the construct featured Arg268, A 
antigen was not detected on the HeLa cells by flow 
cytometric analysis and this mutant construct failed to 
show GTA enzymatic activity.  However, it should be 
noted that the other O2-related SNPs were not present 
in this construct. When the normal and neoplastic 
gastric tissues from the O1O2 patients were stained 
for A antigens, only an equivocal amount of immuno-
reactivity was observed in a few specimens.18
Thus in 2000, the overwhelming weight of 
evidence was on the authors’ side when they con-
cluded18,20 that this allele’s designation as an O allele, 
despite its production of a full-length transcript 
whose protein localizes where functional GTA and 
GTB enzymes do, was valid as it did not appear to 
have enzymatic activity.18
Crystallographic structure of O2 protein reveals 
mechanism for reduced or abolished enzymatic 
activity
More support for classifying O2 as an O allele 
came in 2005 when Lee et al.21 studied an Escherichia 
coli–optimized model of the soluble truncated form 
of the O2 enzyme (lacking amino acids 1–53).  In 
their construct, the O2 enzyme had six orders of 
magnitude less ability to transfer GalNAc to the 
synthetic acceptor substance (H antigen) compared 
with the wild-type GTA enzyme.  Incorporating all 
three amino acid mutations, the activity level (kcat) 
of O2 was 3.4 × 10–5 s–1 compared with the wild-type 
GTA activity of 17.5 s–1 with a GalNAc donor!  The 
soluble form of O2 also had a marked increase in the 
binding constant for the GalNAc donor substrate (KB) 
with a smaller increase for the H antigen acceptor 
substrate (KA).  Moreover, they showed that the prin-
cipal deactivating mutation was Gly268Arg (caused 
by the 802G>A SNP), as revealed in the enzyme’s 
crystal structure; the bulky side chain of Arg268 
causes steric blockade of the access of GalNAc to its 
binding site in the enzyme’s active center, hence the 
observed increase in the KB and its resulting inability 
to catalyze the formation of A antigen.21  Given that 
in the clinical studies described above no A antigens 
were regularly detected on the RBCs or tissues of 
individuals with an O2 gene, and compounded with 
these in vitro data, it looked like the meager kcat of O2 
with a GalNAc donor was basically equal to zero.
Interestingly, the 802G>A SNP turned out not to 
be unique to the O2 family of alleles.  The dbRBC 
contains seven alleles that feature this SNP,11 of which 
two are not specifically identified as group O alleles. 
These others include Aw08 (see below),5 and Bw-18.22 
This latter allele produced a Bx phenotype caused 
by an Ala268Thr amino acid mutation.  Interestingly, 
the steric interference observed with the O2-spe-
cific Arg268 does not appear to occur with Thr268. 
Nevertheless, the kcat of the Bw-18 enzyme is reduced 
by more than 100-fold compared with a wild-type 
GTB with Gal donor, again indicating the importance 
of residue 268 for the enzyme’s activity.22
2. Do O Alleles with 802G>A Give Rise to 
GTA Activity? Yes.
Given the results of all the investigations on the 
O2 allele, it was a surprise when, in 2003, two blood 
donors who were homozygous for nondeletional O 
alleles featuring the 802G>A SNP (also referred to 
as O03 alleles) with an RBC phenotype consistent 
with the Ael subgroup were described.5  Both donors 
also had weak anti-A1 and strong anti-B antibodies 
in their serum.23  One of the two donors had another 
type of nondeletional O allele; in addition to the 
previously reported SNPs for O2, this donor’s allele 
also featured a 488C>T polymorphism, which pre-
dicts a Thr163Met change.  As the authors believed 
that this new nondeletional allele had some intrinsic 
GTA activity, they named it ABO*Aw08 (probably 
identical to O2-4;9 Fig. 1).  It was hypothesized that 
Thr163 somehow allowed the enzyme to overcome 
the significant steric inhibition caused by Arg268, 
thus “reactivating” the enzyme and allowing it to cre-
ate a very weak A phenotype.5  The authors did not 
comment on the fact that although only one donor 
was heterozygous for ABO*Aw08, both donors had 
identical RBC phenotypes.  Thus even the donor who 
was homozygous for two standard nondeletional 
O alleles (O2) without the Thr163Met mutation was 
allegedly capable of producing what they described 
as an Ael phenotype.  This speaks against the notion 
of a reactivating mutation, as does the subsequent 
finding of an apparently identical allele in a blood 
donor with a normal group O phenotype and strong 
anti-A and anti-A1.9
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Allelic enhancement might contribute to the O2 
enzyme’s GTA activity
Allelic enhancement is a phenomenon that can 
lead to unexpected phenotypes, typically noted 
when a pedigree analysis is performed.24  It has been 
reported in the setting of two full-length products 
from the ABO locus; typically one enzyme is mu-
tated and would be expected to produce a weak A 
(or possibly B) phenotype, whereas the second ABO 
glycosyltransferase (GT) is fully functional.  Under 
most circumstances, the normal ABO GT would then 
outcompete the weakened enzyme and can even 
result in the failure to detect any of the mutated 
enzyme’s antigens.25  Uncommonly though, greater 
than expected antigen production by the mutated 
enzyme can result when it is expressed along with 
a fully functional and full-length ABO GT.  In the 
original report, Ax and B alleles were studied in a 
family, and a nearly 10-fold increase in the number 
of RBC A antigen sites was observed in the Ax/B 
family members compared with their Ax/O relatives. 
In addition, serum GTA activity was only detected 
in the Ax/B family members.26  Because wild-type 
GTB is known to have some low-level intrinsic GTA 
activity, it was even more exciting when O2 was im-
plicated in allelic enhancement in a Polish family; the 
propositus demonstrated a weak A phenotype with 
an Ax-4/O2-1 genotype, while her parents both had O 
phenotypes and were heterozygous for Ax-4 or O2-1 
alleles with common deletional O alleles in trans.27 
The biochemical basis of allelic enhancement is still 
unclear, although in an E. coli–optimized model of 
soluble O2 proteins, dimerization appeared to occur 
by means of the enzyme’s stem region.21  Thus, there 
is a potential to produce more enzymatically favorable 
protein heterodimers leading to increased catalysis if 
both fully functional and less optimal ABO-GT are 
present in heterozygous individuals.  A scenario sup-
porting this speculation has recently been reported 
for other types of glycosyltransferases in which the 
enzymatic activity increased significantly after het-
erodimer formation.28
RBCs from blood donors with an O2 allele appear to 
demonstrate A antigens
Seltsam et al.29 followed up their initial report of 
nondeletional group O alleles with limited GTA activ-
ity with a larger survey of both blood donors with a 
group O forward type but variably reduced levels of 
anti-A and normal levels of anti-B on their reverse 
type, samples that were referred to their laboratory 
because of a suspected A subtype, and in vitro ex-
pression studies of both the O2 (O03) allele and the 
ABO*Aw08 allele.  Some of the results were difficult 
to interpret, in particular some of the serologic find-
ings among the 12 donors (and 4 family members) 
who were at least heterozygous for a nondeletional 
O allele.  All but one had an uncomplicated group 
O forward type, although some demonstrated weak-
ening of their serum anti-A1, and some completely 
lacked anti-A.  These reverse typing perturbations 
can be considered a surrogate marker for A antigen 
production, if not on the RBCs themselves then 
perhaps on some other tissue such that the immune 
system produces a muted antibody response to this 
antigen as it recognizes the low level of A antigen 
as a “self” antigen.  In other individuals the level of 
anti-A as assessed by agglutination was normal. A 
antigens were not detectable on any of these RBCs 
by flow cytometry.  Using both polyclonal anti-A and 
anti-A,B, A antigens were barely detectable on some 
of these RBCs using two different adsorption–elution 
techniques,29 which is unusual because even in the 
weakest possible A subgroup, Ael, the eluate generally 
reacts very strongly (typically 3–4+).  In this study, 
Seltsam et al.29 did not report the strength of the 
eluates prepared by using their anti-A and anti-A,B 
reagents with other A subgroup cells as a positive 
control, nor did they specify the results of testing 
the “last wash” supernatant; thus it is unclear how 
to interpret the very weak (often unconventionally 
reported as 0.5+) agglutination they observed in their 
eluates.  Furthermore, the pattern of eluate positiv-
ity is hard to interpret; some donors showed very 
weak reactivity using both eluate methods and both 
reagents, whereas others showed reactivity only with 
one reagent and one eluate method.  The lack of 
consistent eluate reactivity patterns coupled with the 
generally weak agglutination makes drawing firm 
conclusions about the GTA activity of O2 proteins 
difficult in this study.
In this study, one donor who was heterozygous 
for a nondeletional O allele apparently demonstrated 
macroscopically visible agglutination on forward typ-
ing using one particular monoclonal anti-A reagent 
(reported as 1+ agglutination using the Seraclone 
reagent from Biotest AG, Dreieich, Germany), yet 
the donor’s eluate was completely negative with 
both reagents and both elution techniques!29  This 
individual also featured nearly normal agglutination 
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of anti-A1 on reverse typing.  It is difficult to recon-
cile these findings: there were sufficient A antigens 
on this individual’s RBCs to cause macroscopically 
visible agglutination, yet anti-A could not be eluted 
from them, nor was any A antigen detectable by flow 
cytometric analysis.  It must be considered that the 
apparent weak A activity noted in some O2 donors 
and with some reagents may actually represent not 
the true GalNAc-based A antigen but some alterna-
tive A-like structure that cross-reacts with certain 
antisera and sometimes downregulates the anti-A 
response of the individual.  For instance, it should be 
possible to assess whether the O2 protein is slightly 
better at transferring a sugar other than GalNAc to 
the H precursor.  Interestingly, minor reactivity with 
alternative carbohydrate substrates has been reported 
with wild-type GTA and GTB.30
The Aw08 allele was once again detected in two 
donors who had O03/Aw08 genotypes; the presence 
of the Aw08 allele did not cause increased A antigen 
expression on their RBCs compared with those of do-
nors with an O03 allele.29  In the in vitro component 
of their experiments, anti-A was elutable from HeLa 
cells transfected with the O03 and Aw08 genes, and 
eluates from both of these transfections demonstrat-
ed identical agglutination strengths.29  It is possible 
that the transfection experiments do not necessarily 
reflect the activity of these alleles in vivo; the elu-
ates from the RBCs of donors with nondeletional O 
alleles ranged from negative to weakly positive, and 
the strengths did not change significantly between 
eluates prepared from anti-A or anti-A,B reagents. 
In the transfection experiments, the agglutination 
strengths were generally much higher than those 
of the donors, and in all cases showed a full grade 
stronger agglutination with the anti-A,B reagent.29  As 
in their donor studies, Seltsam et al.29 did not report 
the results of the last wash supernatant for the trans-
fection adsorption–elution experiments, nor was this 
technique originally intended to be used on HeLa 
cells.
In their analysis of 16 donors and family members 
with an O2 allele, an interesting side note emerged. 
Although it is difficult to compare the eluate results 
among donors when the strength of agglutination 
was so weak, there did not appear to be a differ-
ence in the diminution of anti-A1 or anti-A on reverse 
typing, nor an increase in strength of the eluates in 
donors who were homozygous for nondeletional O 
alleles compared with those who were heterozygous 
for a deletional O allele.29  This appears to weigh 
against zygosity as a contributing factor in the (pos-
sible) production of A antigen.
Further evidence that homozygosity of non-
deletional O alleles is not required to cause ABO 
discrepancies on automated typing instruments 
came from another German study of 2196 group 
O blood donors by Wagner et al.31  In 45 of these 
samples their Olympus PK7200 could not determine 
the blood group because of irregularities with the 
anti-A reverse typing, and in 38 of those cases, the 
donors were at least heterozygous for an O2 allele 
(1.7% of group O donors).  Given that the expected 
frequency of the O2 allele in the German population 
is approximately 1.6 percent,29,32,33 it was expected 
that in total approximately 65 to 70 donors with at 
least one O2 allele should have been discovered in this 
study.  That only 38 such donors were identified sug-
gests that the allele frequency in that specific donor 
population is lower than expected or, alternatively, 
it is possible that there are other as yet unidentified 
factors that regulate the activity of the O2 protein 
such that in the approximately 30 donors who were 
not identified their O2 protein lacked sufficient GTA 
activity to create an ABO discrepancy.
Curiously, two donors who were heterozygous 
for the O2 allele produced normal levels of anti-A, 
yet they were enumerated among those samples in 
which the instrument could not interpret the ABO 
type because of diminished titers of anti-A.31  In 
this study too, zygosity did not seem to influence 
the diminution of anti-A level; in the 10 donors who 
were devoid of anti-A, all were heterozygous for the 
O03 allele along with a deletional O allele.  Three 
donors were homozygous for nondeletional O alleles, 
and they demonstrated weak (but not absent) anti-A 
on the reverse type, again indicating that zygosity is 
not likely affecting these results, and also that the 
Thr163Met mutation in the Aw08 enzyme does not 
confer on it extra GTA activity compared with the 
O03 (O2) protein.31  Unfortunately, adsorption–elution 
studies were not performed (Franz Wagner, personal 
communication) on the RBCs from the donors with 
an O2 allele to try to determine whether A antigens 
were present or the diminution of anti-A on reverse 
typing had another cause.  Even supplying the levels 
of anti-B would have indicted whether the diminu-
tion in antibody levels was restricted to anti-A (as 
the authors suggest), or it was related to a global 
reduction in antibody titers.
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Although the O2 allele was present in the major-
ity of donors with reduced titers of anti-A, overall the 
results of this study were not clear-cut; there were 
seven donors who were homozygous for deletional 
O alleles who also demonstrated weak anti-A on 
reverse typing.31  Surely another explanation for the 
diminished reverse typing must be sought in these 
donors as deletional O alleles cannot produce A anti-
gens.  Conversely some donors with O03 alleles did 
not demonstrate any diminution of their plasma anti-
A on reverse typing, whereas one O03 heterozygous 
donor demonstrated diminution of both anti-A and 
anti-B on repeat testing.31  The diminution of anti-B 
is not explicable by any intrinsic GTA activity of the 
O2 protein.
In total, these authors have interpreted their 
results to indicate that the members of the O2 family 
of alleles have intrinsic GTA activity.  As Lee et al.21 
reported, the in vitro activity of the soluble form of 
the O2 enzyme was 3.4 × 10–5 s–1; some of the afore-
mentioned results suggest that this number, although 
very small, is not quite equal to zero.  Still, in the 
absence of unusual confounders it can be predicted 
that an A phenotype will be produced if a consensus 
A gene is present and a B phenotype will be produced 
if a wild-type B gene is present.  However, the RBC 
phenotype cannot be predicted with a high degree 
of certainty when a nondeletional O allele is present. 
This is perhaps even more evident in the presence of 
nondeletional O alleles other than O2.9,34
The weak A phenotype created by the O2 allele is 
highly variable
The variability of the O2-associated phenotype 
was highlighted in a recent paper analyzing 19 O2 
heterozygous samples from patients and donors from 
around the world.9  Three samples produced the 
expected normal O phenotype on both the forward 
and reverse typing, 10 samples had diminished or 
absent anti-A in the setting of an otherwise normal 
O phenotype, and in the remaining 6 samples some 
degree of A antigen expression was detected, gener-
ally by adsorption–elution.  A variety of O2 family 
alleles (including a few new family members, i.e., O2 
alleles with one or two additional missense muta-
tions) were detected among these 19 heterozygous 
donors, including Aw08, which was also found in 
a donor with a completely normal O phenotype as 
mentioned above.9
An interesting family study also serves to high-
light the variability of A antigen synthesis in donors 
with an O2 allele.  The male propositus had an 
O1v/O2-2 genotype and an Ael RBC phenotype.  His 
father, who genotyped as O1/O2-2, had a completely 
normal O phenotype including normal-strength anti-
A!  Thus the same allele within the same family can 
behave differently.9
This may be the mechanism for the GTA activity 
associated with the presence of O2
Hosseini-Maaf et al.9 offered an interesting expla-
nation for how an O2 allele might demonstrate GTA 
activity when it is inherited with a common dele-
tional O allele; terming it “autologous chimerism,” 
the authors postulate that if recombination or gene 
conversion occurs between these two O alleles such 
that the 261delG of the deletional allele is replaced 
with the otherwise consensus DNA in this area from 
the nondeletional O allele, then the mRNA from the 
(formerly) deletional O allele will lack the premature 
stop codon and translation can proceed normally. 
This hybrid transcript would not feature the crip-
pling 802G>A SNP characteristic of the O2 family of 
alleles, and thus a functional hybrid A allele could 
be produced.  As this could be a somatic mutation 
occurring randomly during mitosis it would not be 
transmitted from generation to generation.  This 
randomness would explain why the son with the O1v/
O2-2 genotype produced an apparent Ael phenotype, 
whereas his father with basically the same genotype 
did not.  It should be noted that it still remains to 
be shown experimentally whether this appealing 
hypothesis is valid or not.  The fact that other non- 
deletional O alleles carrying early (exon 2) or late 
(exon 6 or 7) nonsense mutations resulting in pre-
mature stop codons behave similarly to O2 in that 
they can produce different phenotypic variants of A 
expression or no A at all favors a general explana-
tion that can be applicable to any combination of a 
deletional and a nondeletional O allele.9,34
However, autologous chimerism, the potential 
process of creating a trans-cis hybrid and in this case 
a functional A allele, would not explain the suspected 
GTA activity in those rare individuals homozygous 
for nondeletional O alleles (O2 is the only example so 
far) because identical alleles cannot overcome each 
other’s problematic polymorphisms.  Finally, it will 
be interesting to see whether a future O allele based 
on a B allele backbone results in a similar phenom-
enon with variable expression of the B antigen.
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3. Do Group O Donors with an 802G>A O2 
Allele Produce A Antigens? Maybe not.
By the end of 2005, several types of studies had 
begun to describe the enigma of the O2 allele: (1) 
studies based on samples referred to a reference 
laboratory because of an ABO discrepancy or suspi-
cion of a weak A subtype phenotype,9,29 (2) studies 
based on blood donors whose predonation samples 
created ABO typing discrepancies,29,31 (3) studies of 
group O blood donors whose predonation samples 
did not feature ABO discrepancies,29 and (4) in vi-
tro studies of the expression and activity of the O2 
allele.13,18,20,21,29
As illustrated above, these studies came to differ-
ent conclusions because of variable results concerning 
the activity and consequences of the O2 allele and 
the encoded O2 enzyme.  In some cases the overall 
conclusion was that the O2 allele was not enzymati-
cally functional, whereas in other studies, there did 
appear to be both direct and indirect evidence for its 
weak enzymatic activity.
Yazer et al.35 took a different approach to the O2 
allele when they studied its incidence and proper-
ties in labeled group O units that were available for 
transfusion from their blood banks in Pittsburgh, 
Pennsylvania, and Lund, Sweden.  The genotypes of 
these group O donors were not known at the time 
of their donation.  These investigators assayed a total 
of 779 group O units for the presence of an O2 allele 
and found 40 donors (5.1%, allele frequency 2.6%) 
who were heterozygous for an O2 allele.  None of 
these units had caused ABO discrepancies either on 
automated ABO typing instruments used for routine 
donor typing or when the ABO type was performed 
manually after these units were identified.  Unlike 
in the previous study of blood donors with an O2 
allele,29 when three donors from Pittsburgh had 
adsorption–elution performed on their RBCs using a 
polyclonal anti-A reagent, anti-A was not recoverable 
in the eluate.  The A antigen was not detected when 
some of these donor RBCs were subjected to a very 
sensitive flow cytometry assay capable of detecting 
the minute quantity of naturally occurring A antigen 
on B cells,36 nor when the plasma from the O2 donors 
was used to upload A antigens onto group O RBCs. 
In fact, the activity of the plasma-borne O2 enzyme 
from these donors was not above the water blank 
baseline.  However, although A antigens could not 
be directly demonstrated on these RBCs, on average 
the titer of anti-A1 and in particular anti-A was clearly 
diminished compared with that from control O1/O1 
sera.35  Unfortunately, titers of other antibodies were 
not performed to exclude a global reduction in im-
munoglobulin titer, but again this appears unlikely 
to coincide with O2 carrier status.  Thus, as described 
earlier, the presence of A antigens on other tissues 
cannot be excluded.
The authors of several earlier studies that had 
shown some weak GTA activity of the O2 protein 
speculated that despite the low level of A antigens 
expressed on these RBCs, it should be safe to trans-
fuse them to group O and B donors who would be 
expected to have naturally occurring anti-A in their 
plasma.29,31  Yazer et al.35 provided some confirma-
tion of this hypothesis by performing a retrospective 
analysis on 19 of the O2 units that were transfused 
to recipients with naturally occurring anti-A.  There 
were no reported immediate hemolytic events, and 
in six recipients for whom more detailed information 
was available, all six had the expected increase in 
their posttransfusion hemoglobin level.  The bio-
chemical markers of hemolysis were not ordered on 
any of the recipients after transfusion, which also 
indicates that the attending clinicians did not suspect 
hemolysis after transfusion of these O2 units.35
In a small prospective study, so far only reported 
in abstract form, the investigators monitored the anti-
A levels in group O recipients after transfusion of 
RBC units from group O donors positive for an O2 
allele (i.e., O03 and Aw08).37  They found no changes 
in these levels when pretransfusion and posttransfu-
sion samples were compared.  This further supports 
the notion that O2 units do not pose a risk of he-
molysis by introducing the A antigen into group O 
recipients.
Conclusions
Whether the O2 protein has consistent GTA activ-
ity remains to be seen, and the factors that regulate 
any intrinsic GTA activity have not been elucidated. 
At most, the O2-encoded protein might be able to 
produce a very weak A phenotype, although in many 
cases evidence for the presence of A antigens on the 
RBCs is indirect, through reduced anti-A1 and anti-A 
levels on reverse typing.  In other situations indi-
viduals with an O2 allele do not seem to demonstrate 
even a weak A phenotype, nor weakened anti-A or 
-A1 in plasma.  In the meantime, the ABO system 
continues to serve as a wonderful model system for 
polymorphic carbohydrate biology, and the study 
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of the O2 protein has shed some more light on the 
fascinating biology of the ABO glycosyltransferases 
and their underlying loci.
References
 1. Yamamoto F, Clausen H, White T, et al. Molecular 
genetic basis of the histo-blood group ABO sys-
tem. Nature 1990;345:229–33.
 2. Yamamoto F, McNeill PD, Hakomori S. Genomic 
organization of human histo-blood group ABO 
genes. Glycobiology 1995;5:51–8.
 3. Bennett EP, Steffensen R, Clausen H, et al. 
Genomic cloning of the human histo-blood 
group ABO locus. Biochem Biophys Res 
Commun 1995;211:347. Erratum for Biochem 
Biophys Res Commun 1995;206:318–25.
 4. Olsson ML, Chester MA. Frequent occurrence of 
a variant O1 gene at the blood group ABO locus. 
Vox Sang 1996;70:26–30.
 5. Seltsam A, Hallensleben M, Kollmann A, et al. 
The nature of diversity and diversification at the 
ABO locus. Blood 2003;102:3035–42.
 6. Hosseini-Maaf B, Hellberg Å, Rodrigues MJ, et 
al. ABO exon and intron analysis in individu-
als with the AweakB phenotype reveals a novel 
O1v-A2 hybrid allele that causes four missense 
mutations in the A transferase. BMC Genet 
2003;4:17 (11 pages electronically published, 
doi:10.1186/1471-2156-4-17).
 7. Roubinet F, Despiau S, Calafell F, et al. Evolution 
of the O alleles of the human ABO blood group 
gene. Transfusion 2004;44:707–15.
 8. Hosseini-Maaf B, Smart E, Chester MA, et al. The 
Abantu phenotype in the ABO blood group sys-
tem is due to a splice-site mutation in a hybrid 
between a new O1-like allelic lineage and the A2 
allele. Vox Sang 2005;88:256–64.
 9. Hosseini-Maaf B, Irshaid NM, Hellberg Å, et al. 
New and unusual O alleles at the ABO locus are 
implicated in unexpected blood group pheno-
types. Transfusion 2005;45:70–81.
 10. Chester MA, Olsson ML. The ABO blood group 
gene: a locus of considerable genetic diversity. 
Transfus Med Rev 2001;15:177–200.
 11. Blumenfeld OO, Patnaik SK. Allelic genes of 
blood group antigens: a source of human mu-
tations and cSNPs documented in the Blood 
Group Antigen Gene Mutation Database. Hum 
Mutat 2004;23:8–16. Available at: http://www
   ncbi.nlm.nih.gov/projects/gv/mhc/xslcgi.cgi? 
cmd=bgmut/home (accessed on 6 December 
2008).
 12. Eiz-Vesper B, Seltsam A, Blasczyk R. ABO gly-
cosyltransferases as potential source of minor 
histocompatibility antigens in allogeneic pe-
ripheral blood progenitor cell transplantation. 
Transfusion 2005;45:960–8.
 13. Yamamoto F, McNeill PD, Yamamoto M, et al. 
Molecular genetic analysis of the ABO blood 
group system: 4. Another type of O allele. Vox 
Sang 1993;64:175–8.
 14. Yazer MH, Palcic MM. The importance of dis-
ordered loops in ABO glycosyltransferases. 
Transfus Med Rev 2005;19:210–16.
 15. Grunnet N, Steffensen R, Bennett EP, et al. 
Evaluation of histo-blood group ABO genotyping 
in a Danish population: frequency of a novel O 
allele defined as O2. Vox Sang 1994;67:210–15.
 16. Olsson ML, Thuresson B, Chester MA. An Ael allele-
specific nucleotide insertion at the blood group 
ABO locus and its detection using a sequence-
specific polymerase chain reaction. Biochem 
Biophys Res Commun 1995;216:642–7.
 17. Olsson ML, Chester MA. Heterogeneity of the 
blood group Ax allele: genetic recombination of 
common alleles can result in the Ax phenotype. 
Transfus Med 1998;8:231–8.
 18. Amado M, Bennett EP, Carneiro F, et al. 
Characterization of the histo-blood group O2 
gene and its protein product. Vox Sang 2000; 
79:219–26.
 19. Irshaid NM, Chester MA, Olsson ML. Allele-re-
lated variation in minisatellite repeats involved 
in the transcription of the blood group ABO 
gene. Transfus Med 1999;9:219–26.
 20. Yamamoto F, McNeill PD. Amino acid residue 
at codon 268 determines both activity and 
nucleotide-sugar donor substrate specificity 
of human histo-blood group A and B transfer-
ases. In vitro mutagenesis study. J Biol Chem 
1996;271:10515–20.
 21. Lee HJ, Barry CH, Borisova SN, et al. Structural 
basis for the inactivity of human blood group 
O2 glycosyltransferase. J Biol Chem 2005;280: 
525–9.
 22. Hosseini-Maaf B, Letts JA, Persson M, et al. 
Structural basis for red cell phenotypic changes 
in newly identified, naturally occurring subgroup
I M M U N O H E M AT O L O G Y,  V O L U M E  2 4 ,  N U M B E R  4 ,  2 0 0 8  147
The O2 allele
  mutants of the human blood group B glycosyl-
transferase. Transfusion 2007;47:864–75.
 23. Seltsam A and Blasczyk R. Evidence for weak 
blood group A phenotypes in individuals 
wih non-deletional ABO*O alleles (abstract). 
Transfusion 2003;43:7A.
 24. Daniels G. Human blood groups. Oxford, United 
Kingdom: Blackwell Scientific, 2002.
 25. Cho D, Kee SJ, Shin JH, et al. Unusual phenotype 
of cis-AB. Vox Sang 2003;84:336–7.
 26. Salmon C, Cartron JP. Le reinforcement allé-
lique. Rev Franc Transfus Immuno-Hémat 1976; 
19:145–55.
 27. Olsson ML, Michalewska B, Hellberg Å, et al. 
A clue to the basis of allelic enhancement: oc-
currence of the Ax subgroup in the offspring of 
blood group O parents. Transfus Med 2005;15: 
435–42.
 28. Seko A, Yamashita K. Activation of β1,3-N-
Acetylglucosaminyltransferase-2 (β3Gn-T2) by 
β3Gn-T8: Possible involvement of β3Gn-T8 in 
increasing poly-n-acetyllactosamine chains in 
differentiated HL-60 cells. J Biol Chem 2008; 
283:33094–100.
 29. Seltsam A, Das Gupta C, Wagner FF, et al. 
Nondeletional ABO*O alleles express weak 
blood group A phenotypes. Transfusion 2005;45: 
359–65.
 30. Seto NO, Compston CA, Szpacenko A, et al. 
Enzymatic synthesis of blood group A and B tri-
saccharide analogues. Carbohydr Res 2000;324: 
161–9.
 31. Wagner FF, Blasczyk R, Seltsam A. Nondeletional 
ABO*O alleles frequently cause blood donor 
typing problems. Transfusion 2005;45:1331–4.
 32. Nishimukai H, Fukumori Y, Okiura T, et al. 
Genotyping of the ABO blood group system: 
analysis of nucleotide position 802 by PCR-
RFLP and the distribution of ABO genotypes in 
a German population. Int J Legal Med 1996;109: 
90–3.
 33. Watanabe G, Umetsu K, Yuasa I, et al. Amplified 
product length polymorphism (APLP): a novel 
strategy for genotyping the ABO blood group. 
Hum Genet 1997;99:34–7.
 34. Yazer MH, Hosseini-Maaf B, Olsson ML. Blood 
grouping discrepancies between ABO genotype 
and phenotype caused by O alleles. Curr Opin 
Hematol 2008;15:618–24.
 35. Yazer MH, Hult AK, Hellberg Å, et al. Investigation 
into A antigen expression on O2 heterozygous 
group O-labeled red blood cell units. Transfusion 
2008;48:1650–7.
 36. Liu QP, Sulzenbacher G, Yuan H, et al. Bacterial 
glycosidases for the production of universal red 
blood cells. Nat Biotechnol 2007;25:454–64.
 37. Scharberg E, Seyboth S, Ernst A, et al. Do donors 
with non-deletional blood group O alleles boost 
anti-A and anti-B titers in blood group O re-
cipients? (abstract). Transfusion 2008;48(Suppl): 
259A.
Mark H. Yazer, MD, FRCPC (corresponding author), 
The Institute for Transfusion Medicine, 3636 Blvd. 
of the Allies, Pittsburgh, PA 15213, and Department 
of Pathology, University of Pittsburgh, Pittsburgh, 
PA; and Martin L. Olsson, MD, PhD, Division of 
Hematology and Transfusion Medicine, Department 
of Laboratory Medicine, Lund University and 
University Hospital Blood Center, Lund, Sweden.
Phone, Fax, and Internet Information: If you have any questions concerning Immunohematology, 
Journal of Blood Group Serology and Education, or the Immunohematology Methods and Procedures 
manual, contact us by e-mail at immuno@usa.redcross.org.  For information concerning the National 
Reference Laboratory for Blood Group Serology, including the American Rare Donor Program, please 
contact Sandra Nance, by phone at (215) 451-4362, by fax at (215) 451-2538, or by e-mail at snance@usa.
redcross.org
